Tissue Regenix Group PLC
LSE:TRX

Watchlist Manager
Tissue Regenix Group PLC Logo
Tissue Regenix Group PLC
LSE:TRX
Watchlist
Price: 0.0725 GBX
Market Cap: 5.2m GBP

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
Operating Income
$-660k
/
Revenue
$26m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
Operating Income
GBX-660k
/
Revenue
$26m

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Tissue Regenix Group PLC
LSE:TRX
5.2m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 76% of companies in United Kingdom
Percentile
24th
Based on 3 579 companies
24th percentile
0%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Tissue Regenix Group PLC
Glance View

Market Cap
5.2m GBX
Industry
Biotechnology

Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. The company is headquartered in Leeds, West Yorkshire and currently employs 79 full-time employees. The company went IPO on 2006-12-21. The firm is focused on the development of regenerative products using its two platform technologies: decellularization (dCELL), which is used to produce allograft (DermaPure) and xenograft (OrthoPure XT) soft tissue products to promote healing and regeneration, and BioRinse, which is a natural bone filler solution verified to be osteoinductive to stimulate and regenerate native bone growth. The firm is engaged in transforming the treatment of patients in surgical applications, including BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology and Cardiac.

TRX Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
0%
=
Operating Income
$-660k
/
Revenue
$26m
What is Tissue Regenix Group PLC's current Operating Margin?

The current Operating Margin for Tissue Regenix Group PLC is 0%, which is in line with its 3-year median of 0%.

How has Operating Margin changed over time?

Over the last 3 years, Tissue Regenix Group PLC’s Operating Margin has increased from -20.8% to 0%. During this period, it reached a low of -20.8% on May 30, 2022 and a high of 1.5% on Dec 31, 2024.

Back to Top